Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 5Other 1Myeloid 1

Conditions

Myelodysplastic Syndromes 4Leukemia, Myeloid, Acute 3Myeloproliferative Disorders 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombosis 1Stomach Neoplasms 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Monoclonal Gammopathy of Undetermined Significance 1Melanoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Neoplasms 1Esophageal Neoplasms 1Disease Progression 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Bone Neoplasms 1Anemia, Aplastic 1

Interventions

Cyclophosphamide 162fludarabine phosphate 127Mycophenolic Acid 96Tacrolimus 92Whole-Body Irradiation 85Busulfan 85Peripheral Blood Stem Cell Transplantation 82fludarabine 79Cyclosporine 68Melphalan 63Antilymphocyte Serum 58Filgrastim 56Methotrexate 55Thiotepa 39Radiotherapy 39Cord Blood Stem Cell Transplantation 34Granulocyte Colony-Stimulating Factor 29Cytarabine 28Methylprednisolone 27Stem Cell Transplantation 26Sirolimus 24thymoglobulin 23Etoposide 23Clofarabine 22Rituximab 19Flow Cytometry 15Cyclosporins 15sargramostim 13Specimen Handling 13Alemtuzumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × Standard of Care × Myeloid × Clear all
NCT05316701 2026-03-04

Orca-T

Orca Biosystems, Inc.

Phase 3 Active not recruiting
187 enrolled 15 charts
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡